Objective: To compare the effectiveness of an in-person versus telephone-based pharmacist-managed lipid clinic.

Methods: Retrospective examination of a pharmacist-managed lipid clinic conducted at a Veterans Affairs medical center between September 2005 and March 2008. The clinical pharmacist educated, monitored, recommended nonpharmacologic treatment, and prescribed lipid-lowering medications using an in-person or telephone-based clinic style. The primary outcomes were to compare the two clinic styles on the percent of patients who reached their low-density lipoprotein (LDL) cholesterol goal and the absolute percent of LDL cholesterol reduction.

Results: 157 patients with coronary artery disease or its risk equivalent were enrolled in the pharmacist-managed lipid clinic. Overall, patients experienced a mean 27% reduction in LDL cholesterol levels from baseline, and 76% reached their LDL cholesterol goal. No significant differences in the percent of patients reaching their LDL cholesterol goal or absolute percent reduction in LDL cholesterol levels were found between the in-person and phone-based clinics. A trend toward phone clinic patients achieving their goal LDL cholesterol levels more quickly was noted.

Conclusion: Both in-person and phone-based pharmacist-managed lipid clinics offer effective methods to improve the cholesterol levels of patients. Phone-based clinics may offer more advantages in efficiency for pharmacists and their patients and the potential to deliver care in a wider variety of pharmacy settings.

Download full-text PDF

Source
http://dx.doi.org/10.1331/JAPhA.2010.09048DOI Listing

Publication Analysis

Top Keywords

ldl cholesterol
28
pharmacist-managed lipid
20
cholesterol levels
16
lipid clinic
12
cholesterol goal
12
in-person versus
8
percent patients
8
cholesterol
8
goal absolute
8
absolute percent
8

Similar Publications

Introduction: Carotid IMT is a recognized marker for early atherosclerotic changes and a predictor of future CV events. Previous studies showed 11% increased risk of myocardial infarction with each 0.1 mm incremental increase of carotid IMT.

View Article and Find Full Text PDF

: This study explores the impact of brown rice bran powder (BRBP), known for its beneficial components, such as dietary fiber and γ-oryzanol, on individuals suffering from metabolic syndrome (MetS). /: In this eight-week open-label controlled trial, fifty participants with MetS were randomly assigned to either a control group, which received a standard diet (SDiet), or an intervention group, which incorporated 15 grams of BRBP daily into their diet. Demographic, anthropometric and clinical data were collected, and blood samples were taken to assess metabolic factors and antioxidant enzyme activities.

View Article and Find Full Text PDF

Atherosclerosis is a progressive arterial disease arising from imbalanced lipid metabolism and a maladaptive immune response. The lymphatic system ensures tissue fluid homeostasis, absorption of dietary fats and trafficking of immune cells to draining lymph nodes, thereby potentially affecting atherogenesis. Endothelial cell-specific deletion of Pannexin1 (Panx1) in apolipoprotein E-deficient (Apoe-/-) mice increased atherosclerosis, suggesting a protective role for Panx1 channels in arterial endothelial function.

View Article and Find Full Text PDF

Debate: Lipid-lowering Therapies and Diabetes Development.

Curr Atheroscler Rep

January 2025

Department of Internal Medicine I, University Hospital Aachen, Pauwelsstraße, 30 52074, Aachen, Germany.

Purpose Of Review: This review explores the relationship between lipid-lowering therapies, particularly statins, and the risk of new-onset diabetes (NOD). It examines the underlying mechanisms and evaluates whether other lipid-lowering agents present similar risks.

Recent Findings: Recent meta-analyses further underscore a dose-dependent increase in NOD risk with statin therapy, particularly with high-intensity statins.

View Article and Find Full Text PDF

Purpose Of Review: Lowering low-density lipoprotein (LDL)-cholesterol reduces cardiovascular risk. International lipid management guidelines recommend LDL-cholesterol goals or thresholds for initiating lipid-lowering therapy. However, contemporary real-world studies have shown that many high- and very high-risk patients are not attaining LDL-cholesterol goals and are not receiving intensive lipid-lowering therapies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!